Cargando…

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers

INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or d...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Euphemia Y., Askarian-Amiri, Marjan E., Sarkar, Debina, Ferraro-Peyret, Carole, Joseph, Wayne R., Finlay, Graeme J., Baguley, Bruce C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591432/
https://www.ncbi.nlm.nih.gov/pubmed/28929082
http://dx.doi.org/10.3389/fonc.2017.00184
_version_ 1783262713309298688
author Leung, Euphemia Y.
Askarian-Amiri, Marjan E.
Sarkar, Debina
Ferraro-Peyret, Carole
Joseph, Wayne R.
Finlay, Graeme J.
Baguley, Bruce C.
author_facet Leung, Euphemia Y.
Askarian-Amiri, Marjan E.
Sarkar, Debina
Ferraro-Peyret, Carole
Joseph, Wayne R.
Finlay, Graeme J.
Baguley, Bruce C.
author_sort Leung, Euphemia Y.
collection PubMed
description INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or deprivation of estrogen, leads initially to inhibition of cell proliferation, followed after several months by the emergence of resistant sub-lines that are phenotypically different from the parental line. We examined the early responses of MCF-7 cells following either exposure to 4-hydroxytamoxifen or deprivation of estrogen for periods of 2 days–4 weeks. METHODS: Endocrine-sensitive or -resistant breast cancer cell lines were used to examine the expression of the stem cell gene SOX2, and the Wnt effector genes AXIN2 and DKK1 using quantitative PCR analysis. Breast cancer cell lines were used to assess the anti-proliferative effects (as determined by IC(50) values) of Wnt pathway inhibitors LGK974 and IWP-2. RESULTS: Hormone therapy led to time-dependent increases of up to 10-fold in SOX2 expression, up to threefold in expression of the Wnt target genes AXIN2 and DKK1, and variable changes in NANOG and OCT4 expression. The cells also showed increased mammosphere formation and increased CD24 surface protein expression. Some but not all hormone-resistant MCF-7 sub-lines, emerging after long-term hormonal stress, showed up to 50-fold increases in SOX2 expression and smaller increases in AXIN2 and DKK1 expression. However, the increase in Wnt target gene expression was not accompanied by an increase in sensitivity to Wnt pathway inhibitors LGK974 and IWP-2. A general trend of lower IC(50) values was observed in 3-dimensional spheroid culture conditions (which allowed enrichment of cells with cancer stem cell phenotype) relative to monolayer cultures. The endocrine-resistant cell lines showed no significant increase in sensitivity to Wnt inhibitors. CONCLUSION: Hormone treatment of cultured MCF-7 cells leads within 2 days to increased expression of components of the SOX2 and Wnt pathways and to increased potential for mammosphere formation. We suggest that these responses are indicative of early adaptation to endocrine stress with features of stem cell character and that this facilitates the survival of emerging hormone-resistant cell populations.
format Online
Article
Text
id pubmed-5591432
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55914322017-09-19 Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers Leung, Euphemia Y. Askarian-Amiri, Marjan E. Sarkar, Debina Ferraro-Peyret, Carole Joseph, Wayne R. Finlay, Graeme J. Baguley, Bruce C. Front Oncol Oncology INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or deprivation of estrogen, leads initially to inhibition of cell proliferation, followed after several months by the emergence of resistant sub-lines that are phenotypically different from the parental line. We examined the early responses of MCF-7 cells following either exposure to 4-hydroxytamoxifen or deprivation of estrogen for periods of 2 days–4 weeks. METHODS: Endocrine-sensitive or -resistant breast cancer cell lines were used to examine the expression of the stem cell gene SOX2, and the Wnt effector genes AXIN2 and DKK1 using quantitative PCR analysis. Breast cancer cell lines were used to assess the anti-proliferative effects (as determined by IC(50) values) of Wnt pathway inhibitors LGK974 and IWP-2. RESULTS: Hormone therapy led to time-dependent increases of up to 10-fold in SOX2 expression, up to threefold in expression of the Wnt target genes AXIN2 and DKK1, and variable changes in NANOG and OCT4 expression. The cells also showed increased mammosphere formation and increased CD24 surface protein expression. Some but not all hormone-resistant MCF-7 sub-lines, emerging after long-term hormonal stress, showed up to 50-fold increases in SOX2 expression and smaller increases in AXIN2 and DKK1 expression. However, the increase in Wnt target gene expression was not accompanied by an increase in sensitivity to Wnt pathway inhibitors LGK974 and IWP-2. A general trend of lower IC(50) values was observed in 3-dimensional spheroid culture conditions (which allowed enrichment of cells with cancer stem cell phenotype) relative to monolayer cultures. The endocrine-resistant cell lines showed no significant increase in sensitivity to Wnt inhibitors. CONCLUSION: Hormone treatment of cultured MCF-7 cells leads within 2 days to increased expression of components of the SOX2 and Wnt pathways and to increased potential for mammosphere formation. We suggest that these responses are indicative of early adaptation to endocrine stress with features of stem cell character and that this facilitates the survival of emerging hormone-resistant cell populations. Frontiers Media S.A. 2017-09-04 /pmc/articles/PMC5591432/ /pubmed/28929082 http://dx.doi.org/10.3389/fonc.2017.00184 Text en Copyright © 2017 Leung, Askarian-Amiri, Sarkar, Ferraro-Peyret, Joseph, Finlay and Baguley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Leung, Euphemia Y.
Askarian-Amiri, Marjan E.
Sarkar, Debina
Ferraro-Peyret, Carole
Joseph, Wayne R.
Finlay, Graeme J.
Baguley, Bruce C.
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title_full Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title_fullStr Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title_full_unstemmed Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title_short Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
title_sort endocrine therapy of estrogen receptor-positive breast cancer cells: early differential effects on stem cell markers
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591432/
https://www.ncbi.nlm.nih.gov/pubmed/28929082
http://dx.doi.org/10.3389/fonc.2017.00184
work_keys_str_mv AT leungeuphemiay endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT askarianamirimarjane endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT sarkardebina endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT ferraropeyretcarole endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT josephwayner endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT finlaygraemej endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers
AT baguleybrucec endocrinetherapyofestrogenreceptorpositivebreastcancercellsearlydifferentialeffectsonstemcellmarkers